Compare Amylx Pharmaceuticals Inc (AMLX) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Moody's Corporation trades at $476.73 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 31.3× Amylx Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MCO | |
|---|---|---|
Market Cap | $2.64B | $82.52B |
Sector | Health | Financials |
52-Week High | $24.19 | $539.61 |
52-Week Low | $7.82 | $412.23 |
Enterprise Value | $2.39B | $88.54B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
